Gimv leads Series B round for Covagen
Swiss biopharmaceutical company Covagen has raised has CHF 42 million in Series B financing. New investor Swiss biopharmaceutical company Covagen has raised CHF 42 million in Series B financing. New investor Gimv led the round with participation from Ascent Biomedical Ventures, Novartis Venture Fund, Edmond de Rothschild Investment Partners, Seroba Kernel Life Sciences, Ventech and MP Healthcare Venture Management. Also, Covagen has named Gimv's Dr. Karl Naegler and Ascent Biomedical Ventures' Dr. Avi Kometz to its board of directors.
10 December 2013•4 mins read
